Recombinant gonadotrophins in reproductive medicine: the gold standard of today

Since the early 1980s when gonadotrophins were first routinely used in ovarian stimulation regimens, there have been important advances in pharmaceutical product development, leading to the availability today of highly purified and consistent human gonadotrophins produced by recombinant technology,...

Full description

Saved in:
Bibliographic Details
Published in:Reproductive biomedicine online 2006, Vol.12 (1), p.11-13
Main Author: Howles, CM
Format: Article
Language:English
Subjects:
Biotechnology - methods
Biotechnology - standards
Female
FSH
Gonadotropins - therapeutic use
Humans
Infertility - drug therapy
ovarian stimulation
Ovulation Induction - methods
Ovulation Induction - trends
purity
recombinant
Recombinant Proteins - therapeutic use
safety
urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the early 1980s when gonadotrophins were first routinely used in ovarian stimulation regimens, there have been important advances in pharmaceutical product development, leading to the availability today of highly purified and consistent human gonadotrophins produced by recombinant technology, that have benefited cycle management and treatment outcomes. This ‘evolution’ has introduced scientifically robust and ‘state of the art’ processes and equipment to ensure that the product is consistent, pure and safe, and is the optimal way to reduce risk of any viral, protein, and bacterial contamination. Production of human proteins by recombinant technology has resulted in improvements in product purity, consistency and delivery as well as enabling the design of future generations of gonadotrophins (e.g. longer-acting forms and orally active mimetics).
ISSN:1472-6483
1472-6491
DOI:10.1016/S1472-6483(10)60973-X